Contract packagers must adapt to surge in serialisation

By Nick Taylor

- Last updated on GMT

Related tags: Service provider

Contract packagers will lose deals if they fail to adapt to biopharm outsourcing “more and more” serialisation work, according to CEO of Covectra.

Proposed serialisation legislation would place additional requirements on biopharm and, in all likelihood, drive demand for service providers capable of handling the work. Increased demand presents a revenue opportunity for contract packagers but there are also challenges and risks.

Contract packagers must be flexible enough to meet the needs of different clients, from the big pharma with its own serialisation numbers to the biotech looking for an end-to-end service, Steve Wood, CEO of Covectra, told Outsourcing-Pharma.

Failure to meet these needs will result in loss of contracts, said Wood. This will begin happening “very soon​” as biopharm launches pilot projects ahead of the “huge, huge undertaking​” of serialising full product portfolios.

Related news

Show more

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

Related suppliers

Follow us

Products

View more

Webinars